MEDVi vs Ro

Both sell tirzepatide. MEDVi costs $399 a month and Ro costs $448, a difference of $49 a month or about $588 a year. The desk reads it as follows.

MEDVi is tablet and injection choice. Ro is branded medication with insurance help. They are not aimed at the same person, and the cheaper one is not automatically the right answer — though on this board it usually is.

Advert against bill. MEDVi advertises $399 and bills $399; Ro advertises $149 and bills $448. The gaps are different sizes, which means comparing the two on their advertised prices gives you the wrong answer.

Side by side

Prices verified 2026-09-18. "True monthly cost" is what you are billed in month two, once any introductory rate has lapsed and any membership has renewed.

The split

They differ on 3 of the 7 things we track, and behave the same on the other 4. The differences are what the price gap is actually buying.

What each puts on the record: MEDVi

• Compounded tirzepatide injections listed at $399/month.
• Tirzepatide tablet pricing is quoted after the intake questionnaire rather than published up front.

Where it wins: Injection pricing is consistent between the first month and renewals. Watch for: You have to complete intake before seeing tablet pricing. Injection pricing is published at $399.

What each puts on the record: Ro

• Ro Body membership is $39 for the first month, then $149/month.
• Membership does not include the cost of GLP-1 medication.
• Ro has exited compounded GLP-1s and works with FDA-approved branded products.
• Effective all-in cost commonly lands between $298 and $598/month depending on the medication and any insurance coverage.
• Cancellation requires notice before the renewal date.

Where it wins: FDA-approved medication only, which removes the compounding-regulation question entirely. Watch for: The membership and the medication are two separate bills. A $39 first month does not mean a $39 prescription.

In each one’s favour

MEDVi.

• Injection pricing is consistent between the first month and renewals.
• Tablet option for people who will not inject.

Ro.

• FDA-approved medication only, which removes the compounding-regulation question entirely.
• Genuine help pursuing insurance coverage.

How they score

Ro scores higher overall at 3.5 out of 5. The weights are published on how we rate, and so is the note about which of these is our paid featured partner.

The desk’s call

• Pick MEDVi if cost is the binding constraint. Over a year the gap is about $588, which is real money for the same class of medication.
• Pick Ro if what it does better matters to you — fda-approved medication only, which removes the compounding-regulation question entirely.
• Ask both which pharmacy compounds the medication and whether it is a 503A or 503B facility. Neither publishes it.

The verdict

On the board, MEDVi at $399 a month is the more defensible choice on arithmetic alone. Ro earns its premium only if you will actually use what it does differently. Read the full reviews before deciding: MEDVi and Ro.

How they sit against everyone else